Compare CRAI & TBPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CRAI | TBPH |
|---|---|---|
| Founded | 1965 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 993.7M |
| IPO Year | 1998 | N/A |
| Metric | CRAI | TBPH |
|---|---|---|
| Price | $206.06 | $18.65 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | ★ $239.00 | $27.80 |
| AVG Volume (30 Days) | 91.9K | ★ 552.8K |
| Earning Date | 10-30-2025 | 11-10-2025 |
| Dividend Yield | ★ 0.94% | N/A |
| EPS Growth | ★ 34.79 | N/A |
| EPS | ★ 8.34 | 0.58 |
| Revenue | ★ $731,055,000.00 | $80,327,000.00 |
| Revenue This Year | $10.57 | $70.78 |
| Revenue Next Year | $3.66 | N/A |
| P/E Ratio | ★ $25.02 | $31.33 |
| Revenue Growth | 8.69 | ★ 27.12 |
| 52 Week Low | $152.57 | $7.90 |
| 52 Week High | $214.66 | $20.33 |
| Indicator | CRAI | TBPH |
|---|---|---|
| Relative Strength Index (RSI) | 73.36 | 58.69 |
| Support Level | $196.75 | $17.25 |
| Resistance Level | $209.88 | $18.36 |
| Average True Range (ATR) | 6.09 | 0.74 |
| MACD | 2.31 | -0.14 |
| Stochastic Oscillator | 93.04 | 59.84 |
CRA International Inc is a U.S.-based advisory firm that provides economic, financial, and management consultancy services. The company advises clients on economic and financial issues relating to litigation and regulatory proceedings and helps businesses set important business strategies and solve performance-related issues. The company's clients include domestic and foreign companies, government agencies, public and private utilities, and national and international trade associations. CRA International generates majority of its revenue from the United States, while it also has its presence in United Kingdom and Other Countries.
Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).